MedTrace Logo

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31889

Last updated 2025-06-25

Study results available
· View outcomes & findings →

Summary

The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S. In this protocol, the investigators propose to generate real-world evidence (RWE) from electronic health records (EHR) and linked claims data to assess the cardiovascular safety of CONTRAVE® and all combined use of naltrexone and bupropion (NB) in usual clinical practice.

Conditions

Sponsors & Collaborators

  • Currax Pharmaceuticals

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06090461 on ClinicalTrials.gov